Abstract Objective To investigate the serum hyaluronic acid (HA), laminin (LN), Ⅳ of the
original (Ⅳ C), Ⅲ procollagen (PC Ⅲ) and total bile acid (TBA) level of content in
chronic liver disease patients changes. Method of radioimmunoassay and enzyme, respectively,
in 250 patients with chronic liver disease in patients with serum HA, LN, IV C, PC Ⅲ and
the level of determination of TBA and 50 normal controls were analyzed. The results between
the groups with chronic liver disease HA, LN, PC Ⅲ, Ⅳ C and TBA levels were
significantly different (P <0.01); HA, LN, Ⅳ C, PC Ⅲ and the increasing tendency for
the TBA: chronic hepatitis (mild ) <chronic hepatitis (moderate) <chronic hepatitis (CAH)
(severe) <liver cirrhosis (LC) <liver cancer (HCC); the levels of serum HA, LN, Ⅳ C, PC
Ⅲ and TBA levels were high in the control group (P <0.01). Conclusions The combined
determination of serum HA, LN, Ⅳ C, PC Ⅲ and TBA levels, while reflecting the severity
of liver fibrosis in patients with liver disease, but also understand the inflammatory
activity and liver cell damage, the clinical diagnosis, treatment and prognosis of important
value.
Liver disease in recent years on serum markers of liver fibrosis in the detection of a new
progress, however, accurately determine the degree of liver fibrosis is currently rely
mainly on detection of liver pathology, but its limitations. So people always looking to
joint monitoring of serum markers of liver fibrosis in the development process. To
investigate the serum hyaluronic acid (HA), laminin (LN), Ⅳ of the original (Ⅳ C), Ⅲ
procollagen (PC Ⅲ) and total bile acid (TBA) in patients with chronic liver changes, we
have 250 patients with liver diseases and 50 normal subjects had serum HA, LN, Ⅳ C, PC
Ⅲ level of content and TBA test, the results reported below.
Subjects and methods
1. Survey
Hospital in-patients were patients with liver disease, male 130 cases, 120 cases of women
aged 30 to 60 years, mean age 41 ± 6 years; which is divided into: chronic hepatitis (mild)
50 cases of chronic hepatitis (moderate) 50 cases, chronic hepatitis (CAH severe 50 cases),
liver cirrhosis (LC) 50 cases of liver cancer (HCC) 50 cases. Diagnostic criteria:
hepatitis, liver cirrhosis diagnosis and clinical classification of the 1995 Fifth National
Conference on Infectious and Parasitic revised classification standards; diagnosis based on
clinical manifestations of liver cancer, AFP and B-test, CT and other results confirmed.
Normal control group of 50 patients, 25 males and 25 females, aged 29 to 58 years, mean age
40 ± 7 years old.
2. Detection.
HA, LN, Ⅳ C, PC Ⅲ using kits by radioimmunoassay using the 262 state-owned production
plants in Xi'an XH 6020γ-immune counter determined. TBA limited liability company with
technology to provide the kit, to use enzyme Hitachi 7060 automatic biochemical analyzer. 3.
Statistical methods measuring data - ± s said that differences between groups using u test,
P <0.05 was statistically significant.
Results
The group of patients with liver disease and normal control group, serum HA, LN, Ⅳ C, PC
Ⅲ, TBA levels were measured in the results were significantly different (P <0.01), and with
the severity of disease increased (P <0.01) concrete in Table 1. Table 1 The serum HA, LN,
Ⅳ C, PC Ⅲ, TBA level was (slightly) Note: The type of liver disease in patients with PC
Ⅲ, HA, LN, Ⅳ C and TBA levels of concentration and the normal control group were
significant (P <0.01). ※ moderate group and mild group compared the test items, P <0.01, △
and the moderate group and severe group comparison of the test items, P <0.01, ▲ cirrhosis
and severe HA, LN, Ⅳ C, TBA comparison , P <0.01, ● cirrhosis group and severe group
compared PC Ⅲ, P <0.05, ○ liver cancer and cirrhosis of the test items compared, P <0.01
